“It’s really hard to tell whether it’s a personality change that can happen because of weight loss or if it’s a side effect because of mood changes,” he added.

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss.

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and ...

As the obesity rate among people with type 1 diabetes rises, patients are taking popular weight loss drugs like Ozempic—and doctors are concerned.

Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when ...

Now, a study of 170,000 patient records suggests there’s a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who ...

Eric Stonestreet Says Mounjaro Was a ‘Game Changer’ for Type 2 Diabetes, Weight Loss: ‘There’s a Pep in My Step' (Exclusive) The ‘Modern Family’ alum tells PEOPLE that he was initially ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over the 2024 average of 8.9% and the 2023 average of 6.9%.